Abstract:There is increasing evidence that many human cancers, including breast cancer, are driven and maintained by cancer stem cells (CSCs) which mediate tumor metastasis and contribute to treatment resistance and relapse. Our group was the first to describe “breast cancer stem cells” (BCSCs) characterized by expression of the cell surface markers ESA and CD44 and the absence of expression of the marker CD24. More recently, we have demonstrated that breast cancer cells contain subpopulations with stem cell properties that can be isolated by virtue of their expression of Aldehyde dehydrogenase (ALDH) as assessed by the Aldefluor assay. Interestingly, these markers identify overlapping, but not identical cell populations. Recent studies have suggested similarities between cancer stem cells and the epithelial mesenchymal transition (EMT) state. Our studies suggest that both normal and malignant breast stem cells exist in distinct, inter-convertible states (EMT and MET), the inter-conversion of which is regulated by microRNAs. EMT-like CSCs have a mesenchymal morphology, are largely quiescent, invasive and characterized by expression of the CSC markers CD24 - CD44 + and are EpCAM - CD49f + . In contrast, the MET (mesenchymal epithelial transition) state of CSCs is characterized by active self-renewal and expression of the CSC markers ALDH and EpCAM + CD49f + . A subpopulation of cells expressing both CD24 - CD44 + and ALDH may represent cells in transition between these states. This transition is regulated by signals originating in the microenvironment which in turn modulate microRNA networks in the CSC populations. The existence of multiple stem cell states suggests the necessity of developing therapeutic strategies capable of effectively targeting CSCs in all of these states. In addition, since CSC states are regulated by miRNAs, these small non-coding RNAs may be useful therapeutic agents to target CSCs.

Rab13 sustains breast cancer stem cells by supporting tumor-stroma crosstalk

Rab13 Sustains Breast Cancer Stem Cells by Supporting Tumor-Stroma Cross-talk.

Supplementary Data from Rab13 Sustains Breast Cancer Stem Cells by Supporting Tumor–Stroma Cross-talk

The Rab2A GTPase Promotes Breast Cancer Stem Cells and Tumorigenesis Via Erk Signaling Activation.

RAB4A is a master regulator of cancer cell stemness upstream of NUMB–NOTCH signaling

The Chemokine Receptor CXCR3 Isoform B Drives Breast Cancer Stem Cells

Beclin 1 and Autophagy Are Required for the Tumorigenicity of Breast Cancer Stem-Like/progenitor Cells

CRB3 Downregulation Confers Breast Cancer Stem Cell Traits Through TAZ/β-catenin

Cancer Stem Cell Regulated Phenotypic Plasticity Protects Metastasized Cancer Cells from Ferroptosis

Mir-376C-3p Modulates the Properties of Breast Cancer Stem Cells by Targeting RAB2A.

Rab37 mediates exocytosis of secreted frizzled-related protein 1 to inhibit Wnt signaling and thus suppress lung cancer stemness

A Novel Lnc408 Maintains Breast Cancer Stem Cell Stemness by Recruiting SP3 to Suppress CBY1 Transcription and Increasing Nuclear Β-Catenin Levels

Role, Molecular Mechanism and the Potential Target of Breast Cancer Stem Cells in Breast Cancer Development

Role of microRNAs in the Regulation of Breast Cancer Stem Cells

Sox2 Communicates with Tregs Through CCL1 to Promote the Stemness Property of Breast Cancer Cells

TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription

Resveratrol Inhibits Breast Cancer Stem-Like Cells and Induces Autophagy Via Suppressing Wnt/β-catenin Signaling Pathway.

Elevated CRB3 Expression Suppresses Breast Cancer Stemness by Inhibiting Β‐catenin Signalling to Restore Tamoxifen Sensitivity

Rab26 suppresses migration and invasion of breast cancer cells through mediating autophagic degradation of phosphorylated Src

Downregulation of CXCR7 Inhibits Proliferative Capacity and Stem Cell-Like Properties in Breast Cancer Stem Cells

Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness.